🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

122 results for “Beone Medicines Ireland Limited” Clear

  1. A Phase 1 Study of BGB-B3227 Alone and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors

    Beone Medicines Ireland Limited

    Solid tumors

    phase 1 other active

    1 trial

  2. A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of BG-75202, Alone and in Combination with Other Agents in Patients with Advanced Solid Tumors

    Beone Medicines Ireland Limited

    Advanced and Metastatic Solid tumors

    phase 1 other active

    1 trial

  3. A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of BG-60366 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

    Beone Medicines Ireland Limited

    EGFR-Mutant Non-Small Cell Lung Cancer

    phase 1 other active

    1 trial

  4. A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

    Beone Medicines Ireland Limited

    Advanced or metastatic solid tumors including hormone receptor positive (HR+), human epidermal growth factor 2 negative (HER2-) breast cancer

    phase 1 other active

    1 trial

  5. A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-53038, a Pan-KRAS Inhibitor, as Monotherapy or in Combinations in Patients With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

    Beone Medicines Ireland Limited

    Advanced or Metastatic Solid Tumors with KRAS Mutations or Amplifications

    phase 1 other active

    1 trial

  6. A Phase 1a/1b, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-75098 Alone and in Combination With Other Agents in Patients With Advanced Solid Tumors

    Beone Medicines Ireland Limited

    Advanced, metastatic or unresectable solid tumors

    phase 1 other active

    1 trial

  7. A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of PRMT5 Inhibitor BGB-58067 Alone and in Combination with Anticancer Agents in Patients With Advanced Solid Tumors

    Beone Medicines Ireland Limited

    Advanced, or metastatic solid tumors with methylthioadenosine phosphorylase (MTAP) homozygous deletion and/or lost MTAP protein expression

    phase 1 other active

    1 trial

  8. AMG 509

    Beone Medicines Ireland Limited

    Prostate Cancer

    phase 1 small molecule active

    1 trial

  9. BG-60366

    Beone Medicines Ireland Limited

    Non-Small Cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

  10. BG-68501

    Beone Medicines Ireland Limited

    Breast Cancer

    phase 1 small molecule active

    1 trial

  11. BG-71332

    Beone Medicines Ireland Limited

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  12. BG-75098

    Beone Medicines Ireland Limited

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  13. BG-75202

    Beone Medicines Ireland Limited

    Breast Cancer

    phase 1 small molecule active

    1 trial

  14. BG-89894

    Beone Medicines Ireland Limited

    Advanced or Metastatic MTAP-deleted Solid Tumors

    phase 1 small molecule terminated

    1 trial

  15. BG-A3004

    Beone Medicines Ireland Limited

    Skin Diseases

    phase 1 mab active

    1 trial

  16. BG-C0902

    Beone Medicines Ireland Limited

    Solid Tumors

    phase 1 small molecule active

    1 trial

  17. BG-C0979

    Beone Medicines Ireland Limited

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  18. BG-C137

    Beone Medicines Ireland Limited

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  19. BG-C477

    Beone Medicines Ireland Limited

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  20. BG-C9074

    Beone Medicines Ireland Limited

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  21. BGB-11417

    Beone Medicines Ireland Limited

    Mature B-cell Malignancies

    phase 1 small molecule active

    1 trial

  22. BGB-15025

    Beone Medicines Ireland Limited

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  23. BGB-16673

    Beone Medicines Ireland Limited

    Chronic Spontaneous Urticaria

    phase 1 small molecule active

    1 trial

  24. BGB-16673

    Beone Medicines Ireland Limited

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources